Targeting the tumor vascular environment with multi-tyrosine kinase inhibitor harboring anti-angiogenic activity (targeting VEGFR, PDGF receptor, and fibroblast growth factor receptor) is the most promising therapeutic option at the moment in relapsed/refractory osteosarcoma but with no known biomarker of efficacy. The gene discussed is KDR; the disease is neoplasm.